Lexeo Therapeutics, Inc.·4

Jun 29, 4:45 PM ET

Altschuler Steven 4

4 · Lexeo Therapeutics, Inc. · Filed Jun 29, 2026

Research Summary

AI-generated summary of this filing

Updated

Lexeo (LXEO) Director Steven Altschuler Receives 35,000-Share Award

What Happened

  • Steven Altschuler, a director of Lexeo Therapeutics (LXEO), was granted a derivative award covering 35,000 shares on 2026-06-25. The Form 4 reports an acquisition price of $0.00 and a reported value of $0 for the transaction. This is a compensation grant (not a purchase or sale) and no shares were sold.

Key Details

  • Transaction date: 2026-06-25; Form 4 filed 2026-06-29 (appears timely — filed within two business days).
  • Grant type: Derivative award (options/award underlying shares) for 35,000 shares at $0.00 reported price.
  • Reported value on Form 4: $0.
  • Shares owned after the transaction: not specified in the provided filing.
  • Vesting note (from filing): 100% of the shares underlying the option vest and become exercisable on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to continuous service.

Context

  • This is a standard director compensation award and does not involve an immediate cash outlay or sale of shares. Such grants are common for board members and reflect compensation rather than a direct cash investment signal.

Insider Transaction Report

Form 4
Period: 2026-06-25
Transactions
  • Award

    Stock Option (right to buy)

    [F1]
    2026-06-25+35,00035,000 total
    Exercise: $4.70Exp: 2036-06-24Common Stock (35,000 underlying)
Footnotes (1)
  • [F1]100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.
Signature
/s/ Youjin Choi, Attorney-in-Fact|2026-06-29

Documents

1 file
  • 4
    form4-06292026_080651.xmlPrimary